Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening

SLAS DISCOVERY(2020)10.1177/2472555220945283Source: DataRank Database

Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening is a research paper published in SLAS DISCOVERY (2020). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access16 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.68)OA: hybridTopics (48)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Michael V. Airola ORCID,Yong‐Mi Choi ORCID,Nicolas Coant ORCID,Justin M. Snider ORCID,Chris Cariello

Live enrichment

PubMed:32734807 OpenAlex:https://openalex.org/W3046758414

National Cancer Institute

Grant: R01CA221948

National Institutes of Health

Grant: 1R01CA221948-01A1

Development of neutral ceramidase inhibitor tool compounds

FWCI

0.68

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttp://slas-discovery.org/article/S247255522206659X/pdf

HYBRIDhttp://slas-discovery.org/article/S247255522206659X/pdf

publisherhttp://slas-discovery.org/article/S247255522206659X/pdf

publisherhttp://journals.sagepub.com/doi/pdf/10.1177/2472555220945283

publisherhttp://journals.sagepub.com/doi/full-xml/10.1177/2472555220945283

Fields of Study

Peptidase Inhibition and AnalysisCarbohydrate Chemistry and SynthesisBiochemical and Molecular ResearchMedicineChemistry0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

AnimalsCell LineDose-Response Relationship, DrugDrug Screening Assays, AntitumorEnzyme ActivationEnzyme InhibitorsHumansSmall Molecule LibrariesNeutral CeramidaseDrug DiscoveryHigh-Throughput Screening Assays

Keywords

High-throughput screeningSmall moleculeChemistryDrug discoveryBiochemistryEnzymeLead compoundDocking (animal)Computational biologyIn vitroCombinatorial chemistryBiologyMedicineDose-Response Relationship, Drugneutral ceramidase570 Biologiepharmacological inhibitorsCell LineHigh-Throughput Screening AssaysEnzyme ActivationSmall Molecule Librariescolon cancerAnimalsHumansHTSfluorescenceddc:570Drug Screening Assays, AntitumorEnzyme Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Novel 8-Methoxycoumarin-3-Carboxamides with potent anticancer activity against liver cancer via targeting caspase-3/7 and β-tubulin polymerization

10.6084/m9.figshare.26648631.v1figshare

Additional file 1 of Novel 8-Methoxycoumarin-3-Carboxamides with potent anticancer activity against liver cancer via targeting caspase-3/7 and β-tubulin polymerization

10.6084/m9.figshare.26648631figshare